Momentum seems to be building behind biotech financings as the first month of 2023 draws to a close, with a respectable raise for cancer start-up Synnovation Therapeutics
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<